Phathom Pharmaceuticals, Inc. P/Operating CF

P/Operating CF of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/Operating CF growth rates and interactive chart. A valuation metric that measures the price of a stock compared to its operating cash flow per share. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low P/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/Operating CF of Phathom Pharmaceuticals, Inc.

Most recent P/Operating CFof PHAT including historical data for past 10 years.

Interactive Chart of P/Operating CF of Phathom Pharmaceuticals, Inc.


Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.